VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH) (OTCQX: AVMXY) announced today that results from a pivotal clinical trial demonstrating the effectiveness and ...
(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket ...
Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has approved the RECELL ® System for the treatment of vitiligo. The ...
An additional presentation at the ABA meeting, awarded best in category at the conference, highlighted preliminary study results demonstrating that donor sites treated with the Spray-On Skin™ Cells ...
Abstracts Highlighting Clinical and Health Economic Data Reinforce Effectiveness of Treatment with RECELL System More than 10,000 Patients treated with RECELL System globally VALENCIA, Calif. and ...
AVITA Medical , a global regenerative medicine company, today announced that the results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL ® ...
Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has expanded the approval of the RECELL ® System to include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results